New treatment for diabetes-related blindness could be in sight

29/11/2018

Pictured: Lead author and Centenary Institute researcher, Dr Ka Ka Ting using Centenary’s state-of-the-art confocal microscope.

Scientists at the Centenary Institute have developed a novel drug which could potentially be used to effectively treat patients with diabetic retinopathy; the main cause of blindness from diabetes.

The key process involved in diabetic retinopathy pathology is the breakdown of the blood-retinal barrier (BRB), which is normally impermeable. Its integrity relies on how well capillary endothelial cells are bound together by tight junctions. If the junctions are loose or damaged, the blood vessels can leak.

In collaboration with researchers in Denmark, scientists at the Centenary Institute in Sydney have demonstrated in mouse models, how a novel drug, CD5-2, can mend the damaged blood retinal barrier and reduce vascular leakage.

“With limited treatment options currently available, it is critical we develop alternative strategies for the treatment of this outcome of diabetes,” says lead author Dr Ka Ka Ting from the Centenary Institute.

Read the full media release.

See the original paper on Diabetologia.

Latest News

Gut microbiome link to deadly lung disease

Research has shown for the first time a link between chronic obstructive pulmonary disease, an often fatal lung condition, and the gut microbiome.

How the humble sea sponge helped scientists unravel a 700 million-year-old mystery of evolution

Researchers have discovered the existence of an ancient genetic code conserved over 700 million years of evolution.

New understanding of how proteins operate

A ground-breaking discovery by Centenary Institute scientists shines new light on the nature of proteins and how they exist and operate in the human body.

 

News Topics

ALL NEWS

 


Sign up for our latest News